The Problem with Delaying Measles Elimination
Measles is a highly infectious disease leading to high morbidity and mortality impacting people’s lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremel...
Uloženo v:
| Vydáno v: | Vaccines (Basel) Ročník 12; číslo 7; s. 813 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
MDPI AG
01.07.2024
|
| Témata: | |
| ISSN: | 2076-393X, 2076-393X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Measles is a highly infectious disease leading to high morbidity and mortality impacting people’s lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality. |
|---|---|
| AbstractList | Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality. Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality.Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality. |
| Audience | Academic |
| Author | Minta, Anna A. Bolotin, Shelly Ariyarajah, Archchun Antoni, Sébastien Bose, Anindya S. O’Connor, Patrick M. Cernuschi, Tania Mulders, Mick N. Crowcroft, Natasha S. |
| Author_xml | – sequence: 1 givenname: Natasha S. orcidid: 0000-0002-6761-8783 surname: Crowcroft fullname: Crowcroft, Natasha S. – sequence: 2 givenname: Anna A. surname: Minta fullname: Minta, Anna A. – sequence: 3 givenname: Shelly surname: Bolotin fullname: Bolotin, Shelly – sequence: 4 givenname: Tania surname: Cernuschi fullname: Cernuschi, Tania – sequence: 5 givenname: Archchun surname: Ariyarajah fullname: Ariyarajah, Archchun – sequence: 6 givenname: Sébastien orcidid: 0000-0002-0911-0711 surname: Antoni fullname: Antoni, Sébastien – sequence: 7 givenname: Mick N. orcidid: 0000-0002-5332-2690 surname: Mulders fullname: Mulders, Mick N. – sequence: 8 givenname: Anindya S. orcidid: 0000-0002-7657-8648 surname: Bose fullname: Bose, Anindya S. – sequence: 9 givenname: Patrick M. surname: O’Connor fullname: O’Connor, Patrick M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39066457$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk1P3DAQhi1EBZRy76mK1EsvobYndpwj4qtIVOUAUm_WxJksXiUxtbOt-Pc1uxTRVWsfPB497zu2Zt6y3SlMxNh7wY8BGv75JzrnJ0pC8pobATvsIEe6hAa-776K99lRSkueVyPA6HqP7We51pWqD1h5e0_FTQztQGPxy8_3xRkN-OinRfGVMA2UivPBj37C2YfpHXvT45Do6Pk8ZHcX57enX8rrb5dXpyfXpVNcziWCwoZap00HTQ2KFLTKyL52SqKQ0ul85W0LouXUSS604sQRmk6qqjcSDtnVxrcLuLQP0Y8YH21Ab9eJEBcW4-zdQFa4igy10kBVVegqVBw6UTVQOepbjdnr08brIYYfK0qzHX1yNAw4UVglC9woIYVsIKMft9BlWMUp_3RNcVWb19QCc30_9WGO6J5M7YnhUNdaK5Op439QeXc0epc72fuc_0vw4bn4qh2pe_n1n15lgG8AF0NKkfoXRHD7NBF2eyKyRG9JnJ_XncyP8cP_hb8BZ1e3eA |
| CitedBy_id | crossref_primary_10_31631_2073_3046_2025_24_3_114_122 crossref_primary_10_3390_vaccines13020157 crossref_primary_10_21070_midwiferia_v11i1_1719 crossref_primary_10_46234_ccdcw2025_094 crossref_primary_10_15585_mmwr_mm7345a4 crossref_primary_10_70749_ijbr_v3i3_600 |
| Cites_doi | 10.1136/bmj.c1626 10.1016/S0140-6736(24)00850-X 10.1093/infdis/jiz159 10.1371/journal.pgph.0001365 10.15585/mmwr.mm7236a3 10.1136/bmj.282.6279.1847 10.15585/mmwr.mm7307a1 10.1016/j.vaccine.2020.07.012 10.1016/j.vaccine.2023.12.004 10.1016/j.lansea.2023.100303 10.4269/ajtmh.16-0802 10.1093/infdis/jis923 10.1542/peds.2019-0630 10.3390/microorganisms10081567 10.1038/s41586-020-03043-4 10.3389/fpubh.2021.689458 10.1016/j.coviro.2020.05.007 10.1016/j.cmi.2017.01.003 10.2807/1560-7917.ES.2019.24.30.1900465 10.1093/infdis/jiac039 10.1016/j.vaccine.2018.12.012 10.1080/16549716.2017.1329968 10.15585/mmwr.mm7133a2 10.1016/j.vaccine.2019.10.090 10.1038/s41467-023-37407-x 10.1016/j.vaccine.2018.01.002 10.4321/S1135-57272015000400002 10.12659/MSM.944436 10.2471/BLT.23.289949 10.1016/S2468-2667(17)30026-9 10.15585/mmwr.mm6819a4 10.26719/2019.25.10.667 10.1093/cid/ciy286 10.1016/S2214-109X(21)00317-X 10.3201/eid2504.181305 10.3389/fpubh.2022.809675 10.15585/mmwr.mm7246a3 10.1016/1047-2797(92)90074-Z 10.1377/hlthaff.2015.1086 10.1377/hlthaff.2020.00103 10.1007/s13346-022-01130-9 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM 3V. 7T7 7XB 8FD 8FE 8FH 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU COVID DWQXO FR3 GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA |
| DOI | 10.3390/vaccines12070813 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Coronavirus Research Database ProQuest Central Engineering Research Database ProQuest Central Student Research Library Prep SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Coronavirus Research Database Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 2076-393X |
| ExternalDocumentID | oai_doaj_org_article_1c4e8eb283444ac4a503d14934cefb6a A803776658 39066457 10_3390_vaccines12070813 |
| Genre | Journal Article Review |
| GeographicLocations | Canada |
| GeographicLocations_xml | – name: Canada |
| GrantInformation_xml | – fundername: World Health Organization grantid: 001 |
| GroupedDBID | 53G 5VS 8FE 8FH 8G5 AADQD AAHBH AAYXX ABUWG ADBBV AEUYN AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO GNUQQ GROUPED_DOAJ GUQSH HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC RNS RPM NPM 3V. 7T7 7XB 8FD 8FK C1K COVID FR3 MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c502t-a35a9ebc68d39735e53b582f7c52a122c6b580bb31b0ed201650e0a39d254f823 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001277520100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2076-393X |
| IngestDate | Fri Oct 03 12:43:47 EDT 2025 Fri Sep 05 12:14:54 EDT 2025 Sun Jul 13 03:24:29 EDT 2025 Sat Nov 29 13:58:38 EST 2025 Tue Nov 04 18:17:59 EST 2025 Mon Jul 21 05:55:56 EDT 2025 Tue Nov 18 21:26:47 EST 2025 Sat Nov 29 07:19:48 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | vaccination programmes waning immunity vaccine equity elimination Measles |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-a35a9ebc68d39735e53b582f7c52a122c6b580bb31b0ed201650e0a39d254f823 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5332-2690 0000-0002-0911-0711 0000-0002-7657-8648 0000-0002-6761-8783 |
| OpenAccessLink | https://www.proquest.com/docview/3085057893?pq-origsite=%requestingapplication% |
| PMID | 39066457 |
| PQID | 3085057893 |
| PQPubID | 2032320 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1c4e8eb283444ac4a503d14934cefb6a proquest_miscellaneous_3085121293 proquest_journals_3085057893 gale_infotracmisc_A803776658 gale_infotracacademiconefile_A803776658 pubmed_primary_39066457 crossref_primary_10_3390_vaccines12070813 crossref_citationtrail_10_3390_vaccines12070813 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Vaccines (Basel) |
| PublicationTitleAlternate | Vaccines (Basel) |
| PublicationYear | 2024 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | McDonald (ref_13) 2019; 68 Guerra (ref_41) 2018; 6 Jankovic (ref_21) 2017; 23 ref_12 Minta (ref_9) 2023; 72 ref_11 ref_10 ref_54 ref_53 Markowski (ref_14) 2013; 207 Masresha (ref_7) 2023; 72 ref_51 Durrheim (ref_26) 2017; 2 Kurata (ref_33) 2024; 42 ref_19 Hughes (ref_40) 2020; 38 ref_18 Bahl (ref_8) 2023; 18 Parums (ref_15) 2024; 30 Rose (ref_17) 1981; 282 Musa (ref_5) 2024; 73 ref_24 ref_23 ref_22 Teleb (ref_1) 2019; 25 ref_20 Byberg (ref_28) 2017; 10 Wang (ref_43) 2023; 14 Lemos (ref_2) 2017; 41 Khanal (ref_35) 2022; 71 Bolotin (ref_46) 2019; 24 Brinkman (ref_44) 2019; 220 Mogaka (ref_38) 2021; 9 ref_36 Ozawa (ref_56) 2016; 35 ref_32 ref_31 ref_30 Krudwig (ref_50) 2020; 38 Sim (ref_37) 2020; 39 ref_39 Tohme (ref_49) 2017; 97 Hinman (ref_29) 1992; 2 Irons (ref_3) 2017; 41 Leuridan (ref_47) 2010; 340 Durrheim (ref_6) 2022; 23 Brown (ref_52) 2020; 41 Goodson (ref_27) 2022; 12 McCoy (ref_55) 2024; 102 Science (ref_48) 2019; 144 ref_45 Truelove (ref_25) 2019; 37 Bolotin (ref_42) 2022; 226 Tami (ref_16) 2019; 25 Muscat (ref_4) 2015; 89 Cherry (ref_34) 2018; 67 |
| References_xml | – volume: 340 start-page: c1626 year: 2010 ident: ref_47 article-title: Early waning of maternal measles antibodies in era of measles elimination: Longitudinal study publication-title: BMJ doi: 10.1136/bmj.c1626 – ident: ref_32 – ident: ref_36 doi: 10.1016/S0140-6736(24)00850-X – volume: 220 start-page: 594 year: 2019 ident: ref_44 article-title: Early Measles Vaccination During an Outbreak in the Netherlands: Short-Term and Long-Term Decreases in Antibody Responses Among Children Vaccinated before 12 Months of Age publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiz159 – volume: 41 start-page: e157 year: 2017 ident: ref_2 article-title: Risk analysis for the reintroduction and transmission of measles in the post-elimination period in the Americas publication-title: Rev. Panam. Salud Publica – ident: ref_39 doi: 10.1371/journal.pgph.0001365 – volume: 72 start-page: 985 year: 2023 ident: ref_7 article-title: Progress toward Measles Elimination—African Region, 2017–2021 publication-title: Mmwr. Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7236a3 – volume: 282 start-page: 1847 year: 1981 ident: ref_17 article-title: Strategy of prevention: Lessons from cardiovascular disease publication-title: Br. Med. J. doi: 10.1136/bmj.282.6279.1847 – volume: 73 start-page: 139 year: 2024 ident: ref_5 article-title: Progress toward Measles Elimination—World Health Organization Eastern Mediterranean Region, 2019–2022 publication-title: Mmwr. Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7307a1 – ident: ref_23 – volume: 38 start-page: 5905 year: 2020 ident: ref_50 article-title: The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia publication-title: Vaccine doi: 10.1016/j.vaccine.2020.07.012 – volume: 42 start-page: 271 year: 2024 ident: ref_33 article-title: Achieving measles elimination and emerging modified measles: Longitudinal measles epidemiology from 1982 to 2021 in Osaka Prefecture, Japan publication-title: Vaccine doi: 10.1016/j.vaccine.2023.12.004 – volume: 18 start-page: 100303 year: 2023 ident: ref_8 article-title: Measles and rubella elimination: Protecting children through immunization in South-East Asia Region (SEAR) publication-title: Lancet Reg. Health Southeast Asia doi: 10.1016/j.lansea.2023.100303 – volume: 97 start-page: 28 year: 2017 ident: ref_49 article-title: Expansion of Vaccination Services and Strengthening Vaccine-Preventable Diseases Surveillance in Haiti, 2010–2016 publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.16-0802 – volume: 207 start-page: 990 year: 2013 ident: ref_14 article-title: Largest Measles Epidemic in North America in a Decade—Quebec, Canada, 2011: Contribution of Susceptibility, Serendipity, and Superspreading Events publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis923 – volume: 144 start-page: e20190630 year: 2019 ident: ref_48 article-title: Measles Antibody Levels in Young Infants publication-title: Pediatrics doi: 10.1542/peds.2019-0630 – volume: 41 start-page: e127 year: 2017 ident: ref_3 article-title: The Expanded Program on Immunization in the English- and Dutch-speaking Caribbean (1977–2016): Reasons for its success publication-title: Rev. Panam. Salud Publica – ident: ref_45 doi: 10.3390/microorganisms10081567 – ident: ref_24 doi: 10.1038/s41586-020-03043-4 – ident: ref_31 doi: 10.3389/fpubh.2021.689458 – ident: ref_10 – volume: 41 start-page: 77 year: 2020 ident: ref_52 article-title: Rapid diagnostic tests to address challenges for global measles surveillance publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2020.05.007 – volume: 23 start-page: 504 year: 2017 ident: ref_21 article-title: Measles and rubella elimination in the WHO Region for Europe: Progress and challenges publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2017.01.003 – volume: 24 start-page: 1900465 year: 2019 ident: ref_46 article-title: Letter to the editor: Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: Low viral load in breakthrough infections publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2019.24.30.1900465 – volume: 226 start-page: 1127 year: 2022 ident: ref_42 article-title: In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiac039 – volume: 37 start-page: 732 year: 2019 ident: ref_25 article-title: Characterizing the impact of spatial clustering of susceptibility for measles elimination publication-title: Vaccine. doi: 10.1016/j.vaccine.2018.12.012 – ident: ref_20 – volume: 10 start-page: 1329968 year: 2017 ident: ref_28 article-title: Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau publication-title: Glob. Health Action doi: 10.1080/16549716.2017.1329968 – volume: 71 start-page: 1042 year: 2022 ident: ref_35 article-title: Progress toward Measles Elimination—South-East Asia Region, 2003–2020 publication-title: Mmwr. Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7133a2 – volume: 38 start-page: 460 year: 2020 ident: ref_40 article-title: The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness—A systematic review publication-title: Vaccine doi: 10.1016/j.vaccine.2019.10.090 – ident: ref_53 – volume: 14 start-page: 1746 year: 2023 ident: ref_43 article-title: Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study publication-title: Nat. Commun. doi: 10.1038/s41467-023-37407-x – ident: ref_30 – volume: 6 start-page: 1248 year: 2018 ident: ref_41 article-title: Immunity of Canadians and Risk of Epidemics (iCARE) Network. Waning of measles maternal antibody in infants in measles elimination settings—A systematic literature review publication-title: Vaccine doi: 10.1016/j.vaccine.2018.01.002 – ident: ref_11 – volume: 89 start-page: 345 year: 2015 ident: ref_4 article-title: The State of Measles and Rubella in the WHO European region publication-title: Rev. Esp. Salud Publica doi: 10.4321/S1135-57272015000400002 – volume: 30 start-page: e944436 year: 2024 ident: ref_15 article-title: A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination publication-title: Med. Sci. Monit. doi: 10.12659/MSM.944436 – volume: 102 start-page: 130 year: 2024 ident: ref_55 article-title: Developing an agenda for the decolonization of global health publication-title: Bull. World Health Organ. doi: 10.2471/BLT.23.289949 – volume: 2 start-page: E130 year: 2017 ident: ref_26 article-title: The price of delaying measles eradication publication-title: Lancet Public Health doi: 10.1016/S2468-2667(17)30026-9 – volume: 23 start-page: 100495 year: 2022 ident: ref_6 article-title: Accelerating measles elimination in the Western Pacific Region during the calm between the storms publication-title: Lancet Reg. Health West. Pac. – volume: 68 start-page: 444 year: 2019 ident: ref_13 article-title: Notes from the Field: Measles Outbreaks from Imported Cases in Orthodox Jewish Communities—New York and New Jersey, 2018–2019 publication-title: Mmwr. Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm6819a4 – ident: ref_18 – volume: 25 start-page: 667 year: 2019 ident: ref_1 article-title: Measles and rubella elimination in the Eastern Mediterranean Region: Successes and challenges publication-title: East. Mediterr. Health J. doi: 10.26719/2019.25.10.667 – ident: ref_54 – ident: ref_12 – volume: 67 start-page: 1315 year: 2018 ident: ref_34 article-title: Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciy286 – volume: 9 start-page: e1359 year: 2021 ident: ref_38 article-title: Why and for whom are we decolonising global health? publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(21)00317-X – volume: 25 start-page: 625 year: 2019 ident: ref_16 article-title: Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2504.181305 – ident: ref_51 doi: 10.3389/fpubh.2022.809675 – volume: 72 start-page: 1262 year: 2023 ident: ref_9 article-title: Progress Toward Measles Elimination—Worldwide, 2000–2022 publication-title: Mmwr. Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7246a3 – ident: ref_19 – volume: 2 start-page: 805 year: 1992 ident: ref_29 article-title: When, where, and how do immunizations fail? publication-title: Ann. Epidemiol. doi: 10.1016/1047-2797(92)90074-Z – ident: ref_22 – volume: 35 start-page: 199 year: 2016 ident: ref_56 article-title: Return on investment from childhood immunization in low- and middle-income countries, 2011–2020 publication-title: Health Aff. doi: 10.1377/hlthaff.2015.1086 – volume: 39 start-page: 1343 year: 2020 ident: ref_37 article-title: Return on Investment from Immunization against 10 Pathogens in 94 Low- and Middle-income countries, 2011–2030 publication-title: Health Aff. doi: 10.1377/hlthaff.2020.00103 – volume: 12 start-page: 959 year: 2022 ident: ref_27 article-title: Innovations in vaccine delivery: Increasing access, coverage, and equity and lessons learnt from measles and rubella elimination publication-title: Drug Deliv. Transl. Res. doi: 10.1007/s13346-022-01130-9 |
| SSID | ssj0000913867 |
| Score | 2.3119931 |
| SecondaryResourceType | review_article |
| Snippet | Measles is a highly infectious disease leading to high morbidity and mortality impacting people’s lives and economies across the globe. The measles vaccine... Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine... |
| SourceID | doaj proquest gale pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 813 |
| SubjectTerms | COVID-19 Disease control elimination Epidemics Feasibility studies Health promotion Immunization Infectious diseases Laboratories Low income areas Measles Morbidity Mortality Pandemics Poliomyelitis Politics Prevention Public health Regions Return on investment Rubella Surveillance vaccination programmes vaccine equity Vaccines waning immunity |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PSx0xEB6KeOhF_FF1W5UUilJwedlks5sc1So9tPIOtngL2SQLwuMp7lPwv3dmsz59FuzF424mkMxkMt_sJt8AfKswKLRemdwgHshLTDBy05oybx0PxC7StD2R9t9f9fm5vrw04xelvuhMWKIHToobFb6MGtM_qgdROl86xWVAWC9LH9um6qERr82LZKrfg00hdVWn_5IS8_rRvfP0p7orUBrDoFyIQz1d_7-b8iuo2Yecs1VYGbAiO0pjXIMPcboO--NENv1wyC6e7051h2yfjZ9pqB82IMdmNk71Yhh9bmU_4sTRrSb2O7puEjt2OulrepFtPsGfs9OLk5_5UBwh94qLWe6kciY2vtIBIYVUUclGadHWXglXCOErfORNI4uGxyDo1hKP3EkTMCVstZCbsDS9nsZtYAXaRMugdFCyjIFjR1c3AY0nvdYhZDB6UpX1A3M4FbCYWMwgSLn2tXIz-D7vcZNYM96QPSbtz-WI77p_gavADqvA_m8VZHBAtrPklTg074bLBThB4reyR5rLuq4QbmWwsyCJ3uQXm5-sbwdv7qwkXj_c2gwO9uu8mXrSCbVpvL5LMoUg9JTBVlo18ynhtKuqVPXn95jqF_goEFilI8M7sDS7vYu7sOzvZ1fd7V7vBo9_JQm_ priority: 102 providerName: Directory of Open Access Journals |
| Title | The Problem with Delaying Measles Elimination |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39066457 https://www.proquest.com/docview/3085057893 https://www.proquest.com/docview/3085121293 https://doaj.org/article/1c4e8eb283444ac4a503d14934cefb6a |
| Volume | 12 |
| WOSCitedRecordID | wos001277520100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M7P dateStart: 20130301 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central - New (Subscription) customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: BENPR dateStart: 20130301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: PIMPY dateStart: 20130301 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M2O dateStart: 20130301 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED_Wdg-DsY_uy1sXNBgdg5rYkmXLT6PdUjZYMjO6kT0ZWZLHICRdnBb6sr99d5bjkA76shdDolOwcj9Jdyfd7wBep7gp1EbmYY72QJiggxHmdZ6EtY4ssYtUdUuk_f1zNpmo6TQvuoBb012rXK-J7UJtF4Zi5ENB3GoIr1y8O_8dUtUoOl3tSmjswB6xJPD26l7Rx1iI81KlmT-dFOjdDy-1ofPqJuYIdRWLrd2oJe3_d2m-ZnC2G8_p_f995QdwrzM52bHHyEO45eb7cFh4zuqrI3a2ScFqjtghKzZs1lf7cNcH9pjPV3oEIYqzwpehYRTFZR_cTFOyFBs73cxcw0aztlQYqfwxfDsdnb3_GHY1F0IjI74KtZA6d5VJlUVLRUgnRSUVrzMjuY45Nyl-jKpKxFXkLKdkqMhFWuQWPc1acfEEdueLuXsGLEZVK2GlslIkzkbYUWeVRUwIo5S1AQzX_31pOkJyqosxK9ExIW2V17UVwNu-x7kn47hB9oTU2csRjXb7xWL5s-xmZRmbxClXcSo2kmiTaBkJiz6jSIyrq1QH8IbAUNJkx1czustZwAESbVZ5rCKRZSlacQEcbEniJDXbzWuIlN0i0ZQbfATwqm-mnnTxbe4WF14Goc1J5qmHYT8kHHaaJjJ7fvOPv4A7HC0xf8f4AHZXywv3Em6by9WvZjmAnWyqBrB3MpoUXwdtSAKfY_5l0M4lev4ZYXvxaVz8-AvIxyO_ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aNiSQEJdxCwwwEgwhLWpi5-I8IDTYplVrqzwUtD0Fx3YQUtWOphvqn-I3ck6ctuqQ9rYHHpMcR3H8-Vxsn-8AvE3QKFQ6zvwM_QE_wgDDz6os8isVGGIXKauGSPtbLx0M5Olplm_An0UuDB2rXOjERlGbiaY18o4gbjWEVyY-nf_yqWoU7a4uSmg4WJzY-W8M2eqP3QMc33ecHx0Ovxz7bVUBX8cBn_lKxCqzpU6kQVssYhuLMpa8SnXMVci5TvAyKEsRloE1nNJ9AhsokRmMpSpJRAeo8rciAvsmbOXdfn62XNUhlk2ZpG4_VIgs6FwqTTvkdchxcslQrNm_pkzAv8bgiovbmLqj-__bT3oA91qnmu27WfAQNux4G3Zzx8o932PDVZJZvcd2Wb7i655vw123dMlcRtYj8FGc5a7QDqN1anZgR4rSwVjfqnpka3Y4aoqhEagfw9cb6doT2BxPxvYZsBDBLIWJpYlFZE2ADVVaGkS90FIa40FnMdaFbinXqfLHqMDQi9BRXEWHBx-WLc4d3cg1sp8JPks5IgpvbkymP4pW7xShjqy0JadyKpHSkYoDYTAqFpG2VZkoD94T-ApSZ_hpWrVZGdhBIgYr9mUg0jRBP9WDnTVJVEN6_fECkkWrButihUcP3iwfU0s62je2kwsnE3JyOz146mC_7BJ2O0miOH1-_ctfw-3jYb9X9LqDkxdwh6Pf6U5U78DmbHphX8ItfTn7WU9ftfOVwfebRv9f39x5Iw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aOoSQEJdxCwwwEgwhLWpi5-I8IDToKqptVR4GGk_BsZ1pUtWOphvqX-PXcU6ctuqQ9rYHHpscR3XynZvt8x2Atwk6hUrHmZ9hPOBHmGD4WZVFfqUCQ-wiZdUQaX8_TIdDeXKS5RvwZ1ELQ8cqFzaxMdRmommNvCuIWw3hlYlu1R6LyHv9T-e_fOogRTuti3YaDiIHdv4b07f646CH3_od5_394y9f_bbDgK_jgM98JWKV2VIn0qBfFrGNRRlLXqU65irkXCf4MyhLEZaBNZxKfwIbKJEZzKsqSaQHaP43MSSPeAc288FR_mO5wkOMmzJJ3d6oEFnQvVSadsvrkKOiyVCs-cKmZcC_juFKuNu4vf79__mFPYB7bbDN9px2PIQNO96Cndyxdc932fGq-KzeZTssX_F4z7fgrlvSZK5S6xH4KM5y14CH0fo169mRojIxdmRVPbI12x81TdII7I_h241M7Ql0xpOxfQYsRJBLYWJpYhFZE-BAlZYGtUFoKY3xoLv47oVuqdipI8iowJSMkFJcRYoHH5Yjzh0NyTWynwlKSzkiEG8uTKanRWuPilBHVtqSU5uVSOlIxYEwmC2LSNuqTJQH7wmIBZk5_GtatdUaOEEiDCv2ZCDSNMH41YPtNUk0T3r99gKeRWse62KFTQ_eLG_TSDryN7aTCycTcgpHPXjqVGA5JZx2kkRx-vz6h7-G2wj54nAwPHgBdziGo-6g9TZ0ZtML-xJu6cvZWT191aoug583Df6_O_6B4w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Problem+with+Delaying+Measles+Elimination&rft.jtitle=Vaccines+%28Basel%29&rft.au=Crowcroft%2C+Natasha+S&rft.au=Minta%2C+Anna+A&rft.au=Bolotin%2C+Shelly&rft.au=Cernuschi%2C+Tania&rft.date=2024-07-01&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=12&rft.issue=7&rft_id=info:doi/10.3390%2Fvaccines12070813&rft_id=info%3Apmid%2F39066457&rft.externalDocID=39066457 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon |